Figures computed from official regulatory filings — .
Analysttarget 25.91 USD (+697%) · consensus 4/5 · 7 buy · 6 hold · 0 sell
Ownershipinsiders 3.52% · institutions 117.67% · short 24.2% of float
In USD · as of Oct 5, 2026
Ask the machine
Search and compare insider transactions, companies and their statistics in plain language. Your question becomes a query over available data, not a conversation or investment advice.
Data for EyePoint, Inc. only. No web search. Global per-insider statistics are excluded.
An executed search uses one credit, even with no results. Errors and unsupported questions use no credits.
EyePoint, Inc. engages in developing and commercializing therapeutics to improve the lives of patients with serious retinal diseases. The company's pipeline leverages its proprietary bioerodible Durasert E technology for sustained intraocular drug delivery. Its lead product candidate is DURAVYU, an investigational sustained delivery treatment for vascular endothelial growth factor mediated retinal diseases combining vorolanib, a selective and patent-protected tyrosine kinase inhibitor with Durasert E which is in Phase 3 clinical trials for wet age-related macular degeneration (wet AMD), and diabetic macular edema (DME). The company's pipeline programs also include EYP-2301, a promising TIE-2 agonist formulated in Durasert E that is in pre-clinical development phase for potentially improve outcomes in serious retinal diseases. The company was formerly known as EyePoint Pharmaceuticals, Inc. and changed its name to EyePoint, Inc. in December 2025. EyePoint, Inc. was founded in 2000 and is headquartered in Watertown, Massachusetts.
Market information source · Oct 5, 2026
Periods recorded in the consulted sources. These do not certify the legal dates of name changes.
SEC company identity · Oct 5, 2026
Open-market timeline · full history
53 buys89 sells— close pricebar = usd volume, √ scaleclick a period to filter the table
| Insider | Type | Value · USD | Signals | Details |
|---|---|---|---|---|
| Elston Georgetrack record | Gift | n/a (Non-cash transaction: the filing states a price of zero (award, gift, exercise)) | SEC |
| Elston Georgetrack record | Other | n/a (Non-cash transaction: the filing states a price of zero (award, gift, exercise)) | SEC |
| Elston Georgetrack record | Other | n/a (Non-cash transaction: the filing states a price of zero (award, gift, exercise)) | SEC |
| Elston Georgetrack record | Gift | n/a (Non-cash transaction: the filing states a price of zero (award, gift, exercise)) | SEC |
| Zaderej Karen L.track record | Buy | $52.3K | conv 52First in 12mo | SEC |
| Duker Jay S. | ExerciseD (derivative) | n/a (Non-cash transaction: the filing states a price of zero (award, gift, exercise)) | SEC |
| Duker Jay S. | Exercise | n/a (Non-cash transaction: the filing states a price of zero (award, gift, exercise)) | SEC |
| Duker Jay S. | Other | $118.6K | SEC |
| Ribeiro Ramiro | Sell | $36.6K | SEC |
| Ribeiro Ramiro | Exercise | $20.1K | SEC |
| Ribeiro Ramiro | ExerciseD (derivative) | n/a (Non-cash transaction: the filing states a price of zero (award, gift, exercise)) | SEC |
| Ribeiro Ramiro | ExerciseD (derivative) | n/a (Non-cash transaction: the filing states a price of zero (award, gift, exercise)) | SEC |
| Ribeiro Ramiro | Sell | $36.6K | SEC |
| Ribeiro Ramiro | Exercise | $20.1K | SEC |
| Elston Georgetrack record | ExerciseD (derivative) | n/a (Non-cash transaction: the filing states a price of zero (award, gift, exercise)) | SEC |
| Elston Georgetrack record | Other | $46.9K | SEC |
| Elston Georgetrack record | Exercise | n/a (Non-cash transaction: the filing states a price of zero (award, gift, exercise)) | SEC |
| Ribeiro Ramiro | Exercise | $20.1K | SEC |
| Ribeiro Ramiro | ExerciseD (derivative) | n/a (Non-cash transaction: the filing states a price of zero (award, gift, exercise)) | SEC |
| Ribeiro Ramiro | Sell | $36.6K | SEC |
| Duker Jay S. | Other | $1M | Unusual size | SEC |
| Duker Jay S. | Other | $1M | Unusual size | SEC |
| Duker Jay S. | OtherD (derivative) | $933.1K | Unusual size | SEC |
| Duker Jay S. | OtherD (derivative) | $459.4K | Unusual size | SEC |
| Duker Jay S. | OtherD (derivative) | $933.1K | Unusual size | SEC |